Targeting transcription factor lysine acetylation in inflammatory airway diseases

Thea van den Bosch, Marcel Kwiatkowski, Rainer Bischoff, Frank J Dekker

Research output: Contribution to journalReview articleAcademicpeer-review

18 Citations (Scopus)
244 Downloads (Pure)

Abstract

Asthma and chronic obstructive pulmonary disease are inflammatory airway diseases for which alternative therapeutic strategies are urgently needed. Interestingly, HDAC inhibitors show anti-inflammatory effects in mouse models for these diseases. Here we explore underlying mechanisms that may explain these effects. In previous studies, effects of HDAC inhibitors on histone acetylation are often correlated with their effects on gene expression. However, effects of HDAC inhibitors on transcription factors and their acetylation status may be particularly important in explaining these effects. These effects are also cell type-specific. Recent developments (including chemoproteomics and acetylomics) allow for a more detailed understanding of the selectivity of HDAC inhibitors, which will drive their further development into applications in inflammatory airway diseases.

Original languageEnglish
Pages (from-to)1013-1028
Number of pages16
JournalEpigenomics
Volume9
Issue number7
DOIs
Publication statusPublished - 1-Jul-2017

Keywords

  • acetylation
  • acetylomics
  • asthma
  • chemoproteomics
  • COPD
  • histone deacetylase
  • inhibitor
  • selectivity
  • HISTONE DEACETYLASE INHIBITORS
  • NF-KAPPA-B
  • OBSTRUCTIVE PULMONARY-DISEASE
  • REGULATORY T-CELLS
  • SELECTIVE HDAC INHIBITORS
  • SEVERE ASTHMA
  • HISTONE/PROTEIN DEACETYLASES
  • INHALED CORTICOSTEROIDS
  • DEPENDENT TRANSCRIPTION
  • RESPONSE ELEMENTS

Cite this